PRIMACYT Cell Culture Technology GmbH provides in-vitro technology services to the pharmaceutical and biotech industry.
It currently offers hepatocyte cells to the drug discovery research community throughout Europe.
The LGC Standards- PRIMACYT partnership is expected to help wider distribution of these cells and promote greater access to important in-vitro models.
LGC Standards MD Elizabeth Jordain said the application and development of improved in-vitro systems as predictors of in-vivo response is a key area of focus for the company’s ADMETox business, and the PRIMACYT partnership creates an ideal opportunity to develop improved systems for in-vitro analysis.
"The collaboration offers opportunities to expand the range of products available in the PRIMACYT portfolio, and develop new distribution channels for important model systems," Jordain said.
PRIMACYT MD Dieter Runge said the partnership with LGC Standards offers an ideal platform from which to implement our product development and expanded distribution initiative.